8 results about "Apoptosis protein" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to lipid nanoparticles as well as a preparation method and application thereof. The invention discloses a lipid nanoparticle. The material of the lipid nanoparticle comprises phospholipid and cholesterol. According to the invention, a lipid nano-carrier delivery system entrapped with apoptotic protein Bax is prepared through a microfluidic technology, and high encapsulation rate and stable delivery of protein drugs are realized. The nano-carrier delivery system capable of actively encapsulating the lipidosome realizes targeted delivery to senescent cells in vivo, so that senescent cell apoptosis is effectively induced, the proportion of senescent cells in tissues is reduced, and a new thought and means are provided for anti-aging treatment.

The invention designs a new application of grape seed procyanidine in prevention and treatment of cataract. The method comprises the following steps: constructing a cataract injury model by inducing rabbit crystalline lens oxidative injury with hydrogen peroxide, culturing by adopting a domestic rabbit crystalline lens, detecting the activity of total superoxide dismutase, glutathione peroxidase and catalase and the content of malondialdehyde by observing the opacity and structural form of the crystalline lens, and detecting the expression of apoptosis regulation proteins BCL-2 and BAX in combination with immunohistochemistry. And the protective effect and molecular mechanism of the grape seed procyanidine on crystalline lens injury are researched. Researches show that the grape seed procyanidine has a protective effect on hydrogen peroxide induced rabbit crystalline lens injury, and the mechanism of the grape seed procyanidine is related to an antioxidant effect and adjustment of BCL-2 / BAX apoptotic protein; rabbit eye stimulation experiments prove that the grape seed procyanidine has no stimulation or only slight stimulation to rabbit eyes. Therefore, the grape seed procyanidine can prevent cataract, is a potential cataract treatment medicine, provides a new way for development of related medical products such as eye drops, and has good clinical application value.

The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and / or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

The invention provides application of frankincense processed product volatile oil in preparation of a medicine. The medicine is used for resisting apoptosis or promoting cell proliferation. The frankincense processed product volatile oil can activate a cAMP signal channel and promote the expression of PKA so as to influence a downstream signal channel, inhibit the phosphorylation of pro-apoptotic protein Bad and promote the expression of anti-apoptotic proteins Bcl-2 and Bcl-xl, thereby effectively inhibiting the apoptosis. Therefore, when the frankincense processed product volatile oil is prepared into the medicine, cell apoptosis can be effectively inhibited, and then cell proliferation is promoted.

The application belongs to the technical field of biomedicine, and particularly relates to application of exogenous recombinant protein ANXA5 in preparation of a medicine for treating cerebral hemorrhage. The application discloses that the expression level of ANXA5 is increased after cerebral hemorrhage; by adding the recombinant ANXA5 protein, the expression level of an iron death related protein can be reduced; meanwhile, the expression level of an apoptosis protein is reversed, the oxidative stress level is slightly reduced, and the levels of MDA and active oxygen water are obviously decreased, which proves that the recombinant protein ANXA5 plays an inhibiting role on neuron iron death after cerebral hemorrhage. The application provides a new type of medicine basis for using the recombinant protein ANXA5 as a treatment for cerebral hemorrhage, especially iron death caused after cerebral hemorrhage.

The present application relates to the technical field of renal cell carcinoma, and particularly relates to a method for predicting the lipid metabolism regulation mechanism of renal cell carcinoma, which is characterized by the following steps: determining the expression difference of EMT, cell proliferation and apoptosis proteins in groups through molecular detection, and determining the difference of fat pathway genes, oil accumulation degree and fat factor expression level in groups, and determining the correlation between lipid metabolism and GAD2, the present project first proposes the miR-metabolic enzyme-lipid pool regulation axis, which is different from the traditional mode of miR directly targeting proliferation genes. Previous studies have focused on the regulation of miRNA on directly related genes such as tumor cell proliferation and apoptosis, and the present project starts from the fat metabolism pathway and deeply explores the regulation of miR-362-5p targeting GAD2 gene on the progression of renal cell carcinoma (RCC). This innovation provides a new perspective and theoretical framework for RCC research, and is expected to open up a new treatment idea, and a systematic research system from clinical samples, cell experiments, molecular detection to animal experiments is constructed.

Disclosed herein are novel 2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine or 1,2,3,4-tetrahydropyrido[2,3-b][1,4]oxazepine derivatives used as antagonists of IAPs (Inhibitors Apoptosis Proteins), also known as Smac mimetics. Disclosed herein is the use of these antagonists for inducing or sensitizing cells to the induction of apoptotic cell death, and the use of such compounds for treating proliferative disease such as cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a PCBP2 overexpression vector in preparation of an MIRI treatment medicine. In order to solve the problem that effective targets for resisting apoptosis of myocardial cells are deficient in treatment of apoptosis-dominated myocardial ischemia reperfusion injury, the invention provides application of a PCBP2 overexpression vector in preparation of an MIRI treatment medicine, and endogenous protein PCBP2 down-regulated in ischemia reperfusion injury is accurately up-regulated through the overexpression vector. The myocardial cell apoptosis balance is efficiently regulated and controlled: the apoptosis rate of the myocardial cells is directly reduced by remarkably up-regulating anti-apoptotic protein Bcl-2 and down-regulating pro-apoptotic protein Bax, and the excessive apoptosis process of the myocardial cells in an apoptosis-dominant injury scene is blocked from the molecular level. According to the invention, dual protection on the myocardial structure and function is realized at the same time, the cardiac function can be improved, the myocardial infarction area can be reduced, and a new candidate strategy is provided for anti-apoptosis treatment of apoptosis-dominated myocardial ischemia-reperfusion injury.